Alachua, FL (PRWEB) January 10, 2013
AxoGen, Inc. (OTCBB: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced today that studies based on clinical use of Avance® Nerve Graft will be presented at the 2013 Annual Meeting of the American Association for Hand Surgery, January 9-12 in Naples, FL. The two studies being presented will report on findings from the RANGER® Registry, an on-going multicenter utilization and outcomes study for Avance® Nerve Graft, a processed nerve allograft for the repair and reconstruction of peripheral nerve segmental defects.
Results from the study, “Recovery Outcomes of Short Gap Sensory Nerve Repairs with Processed Nerve Allografts from Multicenter Registry Study,” will be presented by Brian Rinker, MD, a hand surgeon from the University of Kentucky and an investigator for the RANGER® Registry, on January 11 in Naples, FL. The presentation will report on repairs for 15 subjects with 17 digital nerve injuries with gaps ranging from 5-15 mm in length.
Results from the study, “The Second Data Milestone of an Expanded Enrollment from an Ongoing Multicenter Registry Study on the Use of Processed Nerve Allograft for Sensory, Mixed, and Motor Nerve Reconstructions,” will be presented as a poster by Bauback Safa, MD of The Buncke Clinic and an investigator for the RANGER® Registry. This analysis includes outcomes from 74 repairs on sensory, motor and mixed nerves with gaps of 5 – 50 mm.
“Clinical data to support the use of Avance® Nerve Graft continues to grow,” says Erick DeVinney, Director of Clinical and Translational Science for AxoGen. “We are excited to have additional clinical data provided by experts in the field of peripheral nerve repair.”
Avance® Nerve Graft is processed nerve allograft intended for the reconstruction of peripheral nerve discontinuities to support axon regeneration across the gap and provides surgeons a readily available nerve graft to repair peripheral nerves damaged by traumatic injury or removed during a surgical procedure.
About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.
The RANGER® Registry is sponsored by AxoGen with nominal funding provided to each center to support the data collection process. All data analysis is handled by an independent biostatistician and no surgeon is compensated for implanting Avance® Nerve Graft.
For more information, visit our website at http://www.axogeninc.com.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.
Read the full story at http://www.prweb.com/releases/2013/1/prweb10310126.htm.
Copyright©2012 Vocus, Inc.
All rights reserved